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Each fiscal year, the Health Care Financing Administration (HCFA)
compiles Medicare Part 8 utilization statistics on a state-by-state basis.
These statistics help a carrier understand how its allowed charges for
a particular procedure code compares to the national average for all
carriers. To adjust for uneven beneficiary populations, these statistics
are compiled in terms of the total allowed amounts a carrier allowed
for a procedure per 1 ,000 fee-for-service beneficiaries in its claim
jurisdiction. Carriers are expected to focus their medical data analysis
primarily on the procedures for which its allowed charges per 1,000
beneficiaries substantially exceeded the national average. If necessary
one or more corrective actions are initiated to resolve a utilization
aberrancy after the completion of data analysis and medical research.
For fiscal year 1996, HCFA provided us, and other carriers, utilization
statistics for the first six months of 1995 . This data highlighted the
many procedure codes we allowed at a rate in excess of the national
average during this period. -In orde-r:-to -properly -focus our resources-for
the year, we selected 60 aberrant codes to examine further.
In
selecting the aberrancies for further study, we focused on procedures
for which:
•

Our allowed charges per 1,000 beneficiaries were the most at
variance with the national average;

•

Our annual allowed charges were significant; and

•

Our ability to influence/control utilization was likely.

As a result of this analysis, procedure codes 1 7000-1 7002, the
removal of benign or premalignant skin lesions, were among the codes
selected for further study.
Attachment 1 shows that Florida's
utilization of these codes during the first half of 1995 was 295%
above the national average.
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Our analysis of utilization data and review of relevant medical liter~ture
resulted in the following conclusions:

Conclusions From Data Analysis
•

The aberrancy for procedure codes 1 7000-2 in Florida was
driven primarily by dermatologists, although other specialties
were aberrant as well. In fact, dermatologists in Florida utilized
procedure codes 17001 and 1 7002 more than their peers in any
other state.

•

Florida dermatologists were paid $13,436,640 for the
destruction of benign lesions in the first 6 months of 1995.
This represented approximately 24% of their total Medicare
income.

•

Approximately 50% of the time, the diagnosis associated with
the removal of a benign skin lesion in Florida was actinic
keratosis (AK), a scaly, cutaneous lesion caused by chronic sun
exposure.

•

The practice of treating AKs by destruction was prevalent
throughout Florida.
However, a small number of Florida
dermatologists had a practice of removing an extraordinary
number of AKs during a single patient encounter; for example,
one dermatologist billed for removing approximately 200 AKs
from a patient using a chemical peel.

•

Florida's utilization rate was 1 93 % higher than the average for
other Sun Belt states. (See Attachment 2).

Conclusions From Review of Medical Literature
•

Based on clinical studies about 1 to 2.4 in 1,000 AKs advance
to squamous cell carcinoma (SCC) during a one-year period.

•

The documented metastasis rate for AK-induced SCC also
varies, but is estimated to be between 2%-7%, substantially
less than the metastasis rate for a SCC arising de novo.
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•

The American Academy of Dermatology's guidelines describe
the characteristics of an AK which suggest progression to SCC
(for example, increasing diameter or change of color).

•

Medical literature supports that lesions on certain body parts
such as the lips, nose, ear and eyelids should be treated more
aggressively due to their constant exposure to the elements .

•

Literature indicates that people with a history of skin cancer
should be treated aggressively.

•

For several decades, the use of fluorouracil cream (Efudex) as a
method to destroy A Ks has been well documented.

•

Studies on the removal of AKs for the prevention of SCC are not
conclusive.
In fact, several published physicians have
questioned whether, based on data, treating all AKs would lead
to a reduction in morbidity and mortality associated with SCC.
One example is Marks, R. ( 1991): "The Role of Treatment of
Actinic Keratoses in the Prevention of Morbidity and Mortality
due to Squamous Cell Carcinoma," Archives of Dermatology,
127, 1031-1033. Doctor Marks is a prominent physician who
has done extensive research on the epidemiology and treatment
of AKs.
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Based on the conclusions reached through data analysis and the
review of medical literature, we decided to take three actions:
•

Develop a local medical review policy (LMRP) that describes
when the removal of a benign or premalignant skin lesion would
be considered medically necessary in order to provide a basis for
denial in abusive situations. This policy, which was finalized in
September 1996, is not intended to restrict the removal of AKs
when medically indicated. Instead, it provides for removal under
numerous conditions supported by medical literature, to include:
There is an observable change in the AK, such as size,
color, thickness, etc., or
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The location of the AK is such that the probability of it
becoming an SCC is increased (e.g., the nose, ear, and
eyelids), or
The history of the patient indicates some additional _risk,
such as previous skin malignancy (including SCCs) or
immunosuppression, or
The patient has self-administered fluorouracil and the AKs
have not responded to the treatment regimen.
•

Install a prepayment computer edit that requires adequate
documentation for payment of claims for beneficiaries who have
had more than 15 skin lesions removed in a 90-day period. This
computer edit was installed in November 1996. Therefore,
claims for patients who have had fewer than 1 5 lesions
removed in approximately three months are not suspended for
medical review.

•

Conduct a comprehensive, retrospective review for one
dermatologist who had billed for an extraordinary number of
skin lesion removals. This review resulted in an overpayment
assessment of approximately $140,000, which has been
appealed.
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In short, the process we followed to finalize our LMRP and the related
computer edit is the one specified by HCFA. Specifically, we:
•

Conducted extensive data analysis and medical literature
research prior to concluding that an action was even required or
that the appropriate action was the development of a LMRP.

•

Developed a proposed LMRP for presentation to our Carrier
Advisory Committee (CAC), the physician panel that provides
input on all of our proposed LMRPs. This policy was originally
planned for presentation at the April 1996 meeting of the CAC,
but was withdrawn to allow further dialogue with the
dermatology representative and , through him, his society.
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•

The proposed policy was submitted at the July 1 996 meeting of
the CAC for review and discussion.

•

A 45-day comment period commenced on July 20, 1996, the
day of the CAC meeting. During this comment period( the
dermatology representative on our CAC was very outspoken in
opposition to our LMRP. We had face-to-face meetings and
phone calls with various dermatologists and other medical
professionals throughout and beyond the comment period.

•

Comments received were evaluated and appropriate changes
were made to the proposed LMRP. In short, the dermatologists
favored coverage of AK removal any time the attending
physician deemed it appropriate and, therefore, advocated no
policy at all.

•

The proposed LMRP was shared with Doctor Aron Primack an
Oncologist and the Medical Officer for HCFA's Bureau of
Program Operations. Doctor Primack agreed with our coverage
criteria as outlined in his affidavit prepared as part of the
dermatology litigation (see attachment 4).
Additionally, we
were advised that our policy was shared with the National
Cancer Institute and a dermatologist on HCFA's Physician
Advisory Committee. Neither objected to its content.

•

The LMRP was presented in final form, as approved by our
medical directors, at the September 1996 meeting of the CAC.
At this meeting, the dermatology representative read a letter of
protest into the record. (See Attachment 5). Our response is
included as attachment 6.

•

In October 1996, we released a Bulletin notifying physicians in
Florida of our new LMRP and other LMRPs we had finalized.

•

In November 1996, after providing physicians 30 days advance
notice, we installed a computer edit that requires adequate
documentation for claim payment for beneficiaries who have
had more than 1 5 skin ·Iesion removals in a 90-day period.
Suspended claims submitted with documentation are reviewed
in accordance with our policy.
Assigned claims submitted
without any documentation are denied; unassigned claims
submitted · without documentation result in a request to the
physician for medical documentation.
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The litigation and media/public reaction to our corrective actions
are well known and do not need to be repeated here. We would
like, however, to address three prevalent misunderstandings:
Misunderstanding #1: Our LMRP restricts coverage.

.Ea.ct:

There are many conditions for which the removal of
a benign or premalignant skin lesion is medically
necessary based on our literature research, and as
outlined in our LMRP. These identified conditions are
often overlooked or ignored by those who have
challenged our policy.
Misunderstanding #2:
dictated by the LMRP.

The use of fluorouracil cream is

Fact: The unsuccessful use of fluorouracil cream is only
one of many identified circumstances under which
payment for AK removal may be made. In fact, we added
failure of this treatment regimen to expand our policy's
conditions of coverage. Our LMRP in no way mandates
the use of this cream.
Misunderstanding #3: All claims are being reviewed prior
to payment.
Fact: Only services that fail our computer edit are being
reviewed to ensure compliance with our LMRP. For the
first quarter of 1997~ this represented approximately
8.5% of skin lesion removal services filed to Medicare
Part B.
•

The anticipated impact of our computer edit has been sharply
diminished by coding and pricing changes that HCFA
implemented on January 1, 1997. With these changes HCFA
created its own procedure codes (outside the CPT-4 procedural
coding system) and new fees for the removal of skin lesions.
As a result, a physician is no longer compensated additionally
for removing more than 1 5 lesions daily. The fee for the "1 5 or
6

more lesions" code is capped at
$224.11 per patient
encounter. Prior to 1 997, a physician could bill separately for
.eYfil¥ lesion removed and be compensated $228.65 for the first
1 5 lesions plus $12.48 for each additional lesion. We believe
that the national interest we created was, in part, respoQsible
for this pricing/coding change. Had we been able to effectuate
this change locally, we could have partially addressed utilization
issues associated with the most statistically aberrant physicians
in a more focused and straight forward manner.
Nevertheless, for the first quarter of 1 997, the first full quarter
our screen was operational, we experienced the following:
As stated earlier, 8.5% of services for skin lesion removal
failed our computer edit which resulted in medical review.
Of these failures, 64% were denied or reduced, resulting
in reduced payout of $182, 155 after appeals.
Total
payout was $4,286,243.
•

HCFA has been very supportive of our pos1t1on despite the
intense interest of Congress and organized medicine in this
matter. Secretary Shalala' s response to Congressman Shaw is
included as an example of such support (see attachment 7).

•

In April 1 997 a national work group of Carrier Medical Directors
finalized a "model" medical policy which very closely resembles
our policy and includes many of our medical literature references
including Doctor Marks' publication.
This "model" policy is
intended to serve as a guideline for all Medicare contractors and
has already been adopted by the carriers in Mississippi and
Rhode Island.
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•

Better anticipate and manage public reaction to our actions.

•

Construct policies in a manner that doesn't create inaccurate
impressions or misunderstandings.
For example, the initial
placement of Efudex references in our policy caused some to
misunderstand and misrepresent our intentions.
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•

Carefully pos1t1on our development of Medicare coverage
guidelines within the broader context of good medical practice.
In other words, clearly communicate that the universe of
Medicare covered services is smaller than the universe of what
is perceived as good medical practice.
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